

[1]周泓羽,杜渝平,袁喆.替比夫定对乙型肝炎病毒母婴阻断效果的Meta分析[J].第三军医大学学报,2013,35(20):2220-2225.

Zhou Hongyu, Du Yuping, Yuan Zhe. Efficacy of telbivudine on preventing mother-to-child transmission of hepatitis B virus: a Meta-analysis[J]. J Third Mil Med Univ, 2013, 35(20): 2220-2225.

[点击复制](#)

## 替比夫定对乙型肝炎病毒母婴阻断效果的Meta分析

《第三军医大学学报》 [ISSN:1000-5404/CN:51-1095/R] 卷: 35 期数: 2013年第20期 页码: 2220-2225 栏目: 论著 出版日期: 2013-10-30

**Title:** Efficacy of telbivudine on preventing mother-to-child transmission of hepatitis B virus: a Meta-analysis

**作者:** [周泓羽](#); [杜渝平](#); [袁喆](#)  
重庆医科大学附属第一医院: 预防保健科, 感染科

**Author(s):** [Zhou Hongyu](#); [Du Yuping](#); [Yuan Zhe](#)  
Department of Prevention and Health Care, Department of Infectious Diseases, First Affiliated Hospital, Chongqing Medical University, Chongqing, 400016, China

**关键词:** [肝炎病毒](#); [乙型](#); [替比夫定](#); [母婴传播](#); [效果](#); [荟萃分析](#)

**Keywords:** [hepatitis B virus](#); [telbivudine](#); [mother-to-child transmission](#); [efficacy](#); [meta-analysis](#)

**分类号:** R181.23; R512.62; R978.7

**文献标志码:** A

**摘要:** **目的** 综合评价替比夫定阻断乙型肝炎病毒母婴传播的效果。 **方法** 检索国内外有关替比夫定阻断HBV母婴传播的临床对照试验文献,通过Meta分析方法,对HBV感染孕妇的HBV DNA定量水平及婴儿HBsAg、HBV DNA血清学阳性率进行合并分析。**结果** 替比夫定组孕妇HBV DNA水平较治疗前下降 ( $WMD=3.62$ ,  $95\%CI=3.41\sim 3.82$ ,  $P<0.01$ ),且分娩前HBV DNA水平低于对照组 ( $WMD=-3.51$ ,  $95\%CI=-3.79\sim -3.23$ ,  $P<0.01$ )。婴儿出生后24 h内,替比夫定组的HBsAg阳性率、HBV DNA阳性率分别为11.5%、3.9%,低于对照组的25.8%、17.7% ( $RR=0.45$ ,  $95\%CI=0.32\sim 0.63$ ,  $P<0.01$ ;  $RR=0.26$ ,  $95\%CI=0.15\sim 0.44$ ,  $P<0.01$ )。婴儿6月龄,替比夫定组的HBV DNA阳性率为2.6%,低于对照组的19.2% ( $RR=0.15$ ,  $95\%CI=0.06\sim 0.39$ ,  $P<0.01$ )。婴儿12月龄,替比夫定组的HBsAg阳性率、HBV DNA阳性率分别为3.8%、2.2%,低于对照组的21.5%、16.6% ( $RR=0.18$ ,  $95\%CI=0.09\sim 0.39$ ,  $P<0.01$ ;  $RR=0.15$ ,  $95\%CI=0.06\sim 0.38$ ,  $P<0.01$ )。 **结论** 在孕中后期使用替比夫定进行抗病毒治疗,能够降低孕妇乙肝病毒载量,最终起到较好的乙型肝炎病毒母婴阻断效果。

**Abstract:** **Objective** To evaluate the efficacy of telbivudine on preventing mother-to-child transmission of hepatitis B virus (HBV), and to provide a basis for the prevention and control of mother-to-child transmission of HBV. **Methods** We retrieved the domestic and foreign literatures about controlled clinical trials of telbivudine preventing mother-to-child transmission of HBV. Meta-analysis was

导航/NAVIGATE

[本期目录/Table of Contents](#)

[下一篇/Next Article](#)

[上一篇/Previous Article](#)

工具/TOOLS

[引用本文的文章/References](#)

[下载 PDF/Download PDF\(960KB\)](#)

[立即打印本文/Print Now](#)

[查看/发表评论/Comments](#)

[导出](#)

统计/STATISTICS

[摘要浏览/Viewed](#) 108

[全文下载/Downloads](#) 60

[评论/Comments](#)

[RSS](#) [XML](#)

used to analyze HBV DNA level of HBV-infected pregnant women, and HBsAg and HBV DNA seropositivity of infants. Results The HBV DNA level of pregnant women of telbivudine group was decreased after treatment (WMD=3.62, 95% CI=3.41 to 3.82,  $P<0.01$ ), and was lower than those in control group before parturition (WMD=-3.51, 95%CI=-3.79 to -3.23,  $P<0.01$ ). Within 24 hours after infants birth, the seropositivity of HBsAg and HBV DNA of telbivudine group infants were 11.5% and 3.9% respectively, lower than those in control group, 25.8% and 17.7% respectively ( $RR=0.45$ , 95%CI=0.32 to 0.63,  $P<0.01$ ;  $RR=0.26$ , 95%CI=0.15 to 0.44,  $P<0.01$ ). The HBV DNA seropositivity of 6-month infants from telbivudine group was 2.6%, lower than 19.2% for the control group ( $RR=0.15$ , 95%CI=0.06 to 0.39,  $P<0.01$ ). The seropositivity of HBsAg and HBV DNA of 12-month infants from telbivudine group were 3.8% and 2.2% respectively, lower than 21.5% and 16.6% for the control group ( $RR=0.18$ , 95%CI=0.09 to 0.39,  $P<0.01$ ;  $RR=0.15$ , 95%CI=0.06 to 0.38,  $P<0.01$ ). Conclusion Telbivudine treatment during the second and third trimester of pregnancy reduces HBV DNA level in pregnant women, and ultimately prevents mother-to-child transmission of HBV.

#### 参考文献/REFERENCES:

周泓羽, 杜渝平, 袁喆. 替比夫定对乙型肝炎病毒母婴阻断效果的Meta分析[J]. 第三军医大学学报, 2013, 35(20):2220-2225.

#### 相似文献/REFERENCES:

[1]田小利,秦波.趋化因子与干扰素治疗慢性乙型肝炎学应答的相关性[J]. 第三军医大学学报, 2012, 34(16):1668.

Tian Xiaoli, Qin Bo. Relationship between chemokine levels and virological response to PegIFN $\alpha$ -2a treatment in patients with chronic hepatitis B[J]. J Third Mil Med Univ, 2012, 34(20):1668.

[2]刘霖, 汤影子, 王宇明, 等. 构象敏感凝胶电泳用于检测乙型肝炎病毒P区核苷类似物耐药准种的初步研究[J]. 第三军医大学学报, 2007, 29(21):2103.

[3]唐玉兰, 谭文婷, 谭顺, 等. 282例散发性戊型肝炎流行病学及临床特征分析[J]. 第三军医大学学报, 2011, 33(11):1178.

Tang Yulan, Tan Wenting, Tan Shun, et al. Epidemiological and clinical characteristics of sporadic hepatitis E: A report of 282 cases[J]. J Third Mil Med Univ, 2011, 33(20):1178.

[4]刘明, 邓国宏, 谭顺, 等. 慢加急性肝衰竭前期临床常规预警指标研究[J]. 第三军医大学学报, 2012, 34(08):772.

Liu Ming, Deng Guohong, Tan Shun, et al. Routine early clinical warning indicators of acute-on-chronic pre-liver failure[J]. J Third Mil Med Univ, 2012, 34(20):772.

[5]田沂, 唐晓鹏, 杨旭, 等. HBV标志物定量与病毒载量关系探讨[J]. 第三军医大学学报, 2007, 29(13):1305.

TIAN Yi, TANG Xiao-peng, YANG Xu, et al. Correlation of virus load to contents of serologic markers in HBV patients[J]. J Third Mil Med Univ, 2007, 29(20):1305.

[6]谭文婷, 邓国宏, 王宇明, 等. 重庆地区乙肝病毒基因型分布及其临床意义[J]. 第三军医大学学报, 2008, 30(24):2321.

TAN Wen-ting, DENG Guo-hong, WANG Yu-ming, et al. HBV genotype distribution and its influences on progression of HBV-related chronic liver disease in Chongqing population[J]. J Third Mil Med Univ, 2008, 30(20):2321.

[7]李丹, 丁健, 林纳, 等. 乙型肝炎病毒PreS1蛋白与初期多肽相关复合体 $\alpha$ 亚单位特异性结合的研究[J]. 第三军医大学学报, 2009, 31(23):2315.

LI Dan, DING Jian, LIN Na, et al. Interaction between hepatitis B virus PreS1 protein and nascent-polypeptide-associated complex alpha polypeptide[J]. J Third Mil Med Univ, 2009, 31(20):2315.

[8]万涛, 张小花, 张磊, 等. HBV对肝癌细胞中AKR1C1基因表达的影响[J]. 第三军医大学学报, 2010, 32(03):297.

[9]张长江, 熊瑜琳, 谭朝霞, 等. 阿德福韦联合恩替卡韦治疗多药物作用后慢性乙型肝炎的早期疗效评估及其影响因素分析[J]. 第三军医大学学报, 2010, 32(22):2413.

Zhang Changjiang, Xiong Yulin, Tan Zhaoxia, et al. Early response to adefovir and entecavir combination in chronic hepatitis B patients after multi-antivirus drugs sequential therapy and influencing factors[J]. J Third Mil Med Univ, 2010, 32(20):2413.

[10]黄亚琴, 杨丽莎, 吴淋玲. HBV基因型在HBV感染性肝癌及慢性HBV感染自然史不同阶段的分布[J]. 第三军医大学学报, 2011, 33(12):1258.

Huang Yaqin, Yang Lisha, Wu Linling. Distribution of HBV genotypes in HBV infection-associated hepatocellular carcinoma and in different phases of natural chronic HBV infection history[J]. J Third Mil Med Univ, 2011, 33(20):1258.